Compare ProShares Ultra QQQ ETF (QLD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? ProShares Ultra QQQ ETF trades at $90.63 (market cap $15.24B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: ProShares Ultra QQQ ETF is far larger — about 2× Spyre Therapeutics Inc. Common Stock's market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 36 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| QLD | SYRE | |
|---|---|---|
Market Cap | $15.24B | $7.52B |
Volume | 2,898,706 | 1,441,031 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $108.92 |
52-Week Low | $57.16 | $22.18 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $96.42, down 0.68% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF provides 2x leveraged exposure to the Nasdaq-100 index, positioning it as a less volatile alternative to triple-leveraged products during market downturns. Recent institutional buying by 180 Wealth Advisors LLC increased their position by 29.4% in Q2 2026, signaling confidence in the fund's strategy.
The outlook for QLD remains tied to Nasdaq-100 performance, with technical support at $95-$97 and resistance at $98-$99. While leveraged ETFs offer amplified returns, they carry elevated risk from daily rebalancing and market volatility. Investors should monitor Fed policy impacts and tech sector momentum for directional cues, with the current setup favoring tactical positions above key support levels.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
